Clinical Trials Directory

Trials / Completed

CompletedNCT06693154

Calprotectin Levels in Necrotizing Enterocolitis

A Comparative Study of Serum and Fecal Calprotectin Levels in Necrotizing Enterocolitis

Status
Completed
Phase
Study type
Observational
Enrollment
59 (actual)
Sponsor
Ankara Yildirim Beyazıt University · Academic / Other
Sex
All
Age
3 Days – 30 Days
Healthy volunteers
Not accepted

Summary

Necrotizing enterocolitis (NEC) is a serious condition that can affect premature babies, leading to complications like intestinal damage and infection. In our study, we measured specific markers (called calprotectin) in blood and stool to understand how severe NEC is and predict outcomes. We found that these markers were higher in babies with more severe NEC (stage 3), especially in those who needed surgery or sadly did not survive. This information can help doctors detect NEC earlier, understand its severity, and make better decisions for treating affected babies.

Conditions

Timeline

Start date
2022-06-01
Primary completion
2024-01-01
Completion
2024-06-01
First posted
2024-11-18
Last updated
2024-11-18

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT06693154. Inclusion in this directory is not an endorsement.

Calprotectin Levels in Necrotizing Enterocolitis (NCT06693154) · Clinical Trials Directory